with growth. CMD is a rare disease that is often misdiagnosed. An accurate and early diagnosis and knowledge of the natural history of CMD is important for establishing preventative treatment regimens and proper management of complications as well as estimating the prognosis.

References

1. Feingold M. 28-year follow-up of the craniofacial findings in a patient with craniometaphyseal dysplasia. Am J Med Genet 1999;86:501-2.
2. Jackson WP, Albright F, Drewry G, et al. Metaphyseal dysplasia, epiphysyal dysplasia, diaphyseal dysplasia, and related conditions. I. Familial metaphyseal dysplasia and craniometaphyseal dysplasia; their relation to leontiasis ossea and osteopetrosis; disorders of bone remodeling. AMA Arch Intern Med 1954;94:871-85.
3. Beighton P. Craniometaphyseal dysplasia (CMD), autosomal dominant form. J Med Genet 1995;32:370-4.
4. Lamazza L, Messina A, D’Ambrosio F, et al. Craniometaphyseal dysplasia: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:e23-7.
5. Richards A, Brain C, Dillon MJ, et al. Cranioetaphyseal and craniodiaphyseal dysplasia, head and neck manifestations and management. J Laryngol Otol 1996;110:328-38.

Primary mucinous carcinoma of the skin (MCS) is a rare sweat gland tumor, with approximately 175 cases reported in the literature since the first case was described by Lennox et al. [1] in 1952. Although MCS is usually slow growing, it often shows locally aggressive behavior and a high rate of local recurrence following simple excision. The clinical appearance and differential diagnosis of MCS vary, but histopathologically MCS is similar to metastatic carcinomas, specifically of the breast and colon. The recognition of MCS is essential for preventing an erroneous diagnosis of

Neuroendocrine Differentiation of Primary Mucinous Carcinoma of the Cheek Skin

So-Eun Han1, So Young Lim1, Ha Seong Lim2

1Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; 2I’m Skin Clinic, Seoul, Korea

Correspondence: So Young Lim
Department of Plastic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Inwon-ro, Gangnam-gu, Seoul 135-710, Korea
Tel: +82-2-3410-2235, Fax: +82-2-3410-0038
E-mail: sy72.lim@samsung.com

Received: 19 Oct 2012 • Revised: 14 Jan 2013 • Accepted: 15 Jan 2013
gISSN: 2234-6163 • eISSN: 2234-6171
http://dx.doi.org/10.5999/aps.2013.40.2.159 • Arch Plast Surg 2013;40:159-162
Copyright © 2013 The Korean Society of Plastic and Reconstructive Surgeons
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fig. 4.
(A) Axial view of a facial computed tomography (CT) scan shows diffuse thickening of the cranial base, reduced pneumatization of both mastoid air cells, and narrowing of the cranial nerve foramina by hyperostosis. (B) Three-dimensional facial CT scan shows unusually prominent zygoma, maxilla, and mandible. Increased interorbital distance and a widened nasal bridge can also be seen.
metastatic carcinoma. In Korea, to our knowledge, only 1 of 9 cases that have been reported was diagnosed as neuroendocrine differentiation [2]. Kim et al. [2] reported a case of primary mucinous carcinoma with neuroendocrine differentiation, focusing on its clinical and histologic features. In the present study, we report a case of MCS with neuroendocrine differentiation on the cheek that was treated with wide excision and a rotation advancement cheek flap, which showed favorable results. This article is focused on the distinctive pathological findings, the surgical approach, and the postoperative evaluation process of neuroendocrine differentiation of MCS.

A 72-year-old man presented with a 3-year history of an asymptomatic 15 × 20 mm, well-demarcated, erythematous nodule growing on his left cheek (Fig. 1). He had first noticed this lesion 3 years prior and became concerned as it slowly enlarged. An incisional biopsy demonstrated mucinous eccrine carcinoma with positive margins. Under general anesthesia, the tumor was excised with 2 cm margins, according to oncological principles, as a full-thickness specimen. The regional lymph nodes were not involved. The surgical defect measured 5.5 × 6.0 cm (Fig. 2). Although he was an elderly patient, his skin laxity was limited. Therefore, extensive undermining was performed in the surrounding facial region in the subcutaneous plane and stopped at the lower border of the mandible; there was no undermining in the cervical region. The rotation flap was progressively elevated until there was adequate flap mobilization to cover the defect area and tension-free closure was possible (Fig. 3). The histologic examination revealed aggregates of glandular epithelioid cells floating in mucinous pools that were defined by thin, fibrous septa. The pools of mucin stained positive for Alcian blue at pH 2.5 and periodic acid-Schiff. Immunohistochemical staining demonstrated positive reactions to synaptophysin (Fig. 4), estrogen receptors (ER), progesterone receptors (PR), and cytokeratin 7, and a negative reaction to cytokeratin 20, which met the description of markers positive for neuroendocrine differentiation. A full metastatic workup was performed, including computed tomography (CT) and positron emission tomography (PET) scans, without evidence of another primary type of cancer. Two years after surgery, the patient remains in good health without recurrence, showing good aesthetic results (Fig. 5).

Histologically, MCS may appear similar to other sweat gland tumors and metastatic carcinomas. Immunohistochemical staining of MCS cells with Alcian blue, which shows positive at a pH of 2.4, but negative
at a pH of 4.0, can differentiate MCS from other sweat gland tumors [3]. Gastrointestinal carcinomas contain sulfomucin, while sialomucin is present in MCS [3]. Cytokeratin 20 is common in gastrointestinal neoplasms, but absent in MCS [3]. Cytokeratin 7 and p63 can be found in MCS, but are rarely found in metastatic tumors [3]. Positive immunohistochemical staining for synaptophysin, cytokeratin 7, ER, and PR with a negative reaction to cytokeratin 20, indicates neuroendocrine differentiation [3]. Since 1980, neuroendocrine differentiation of mucinous carcinoma of the breast has been reported according to a type A (without neuroendocrine differentiation), type B (with neuroendocrine differentiation), and type AB (intermediate form) classification [4]. Two previous studies have shown that good prognosis was found in mucinous carcinoma of the breast showing neuroendocrine differentiation [4]. The exact component ratio of neuroendocrine differentiation among mucinous cutaneous carcinoma has not been reported yet [2]. A full oncologic evaluation to search for other primary cancer sites is required for all patients with sweat gland tumors to distinguish MCS from metastatic tumors.

MCS is unresponsive to chemotherapy and is radiation-resistant. Given the high rate of local recurrence and the low rate of distant metastases, the gold standard treatment is excision of the tumor. Although local excision with narrow 2 mm margins is sometimes sufficient for superficial tumors, local recurrence has been reported following excision with a 1 cm margin in at least one case. There has been one case report with no evidence of recurrence or metastasis for 10 months postoperatively following resection with 1.5 cm to 2.0 cm margins [5].

For small cheek skin defects (less than 4 cm), the cheek rotation flap described by Mustarde generally allows for easy coverage without complications. When there is no skin laxity, a more extensive undermining in the facial region is necessary to cover the defect [5]. Cervicofacial flaps are helpful for larger cheek skin defects with a wider flap elevation and undermining. However, the resultant closure often has tension when occurring on the cheek, requiring larger incisions and undermining, which can result in compromised vascularity and vulnerability to ischemic necrosis on the distal end of the flap. For the 6 cm cheek defect in our case, the rotation advancement cheek flap with subcutaneous undermining only to the mandible border while preserving the cervical region allowed for good coverage without complications. The flap color and texture was well matched with the surroundings without flap loss.

The slow growing and clinically asymptomatic features of MCS can delay the diagnosis, and to rule out other sources of metastatic mucin-secreting carcinomas to the skin, an imaging scan (CT, magnetic resonance imaging [MRI] or PET) is always required. Due to the locally aggressive behavior and high rate of local recurrence of MCS, surgical excision with a wide safety margin is required, and an annual follow-up with detailed systemic examination is recommended. For MCS with local recurrence and lymph...
Hemangiopericytoma in the Nasolabial Fold

Tae Kyung Eom¹, Seok Joo Kang¹, Jin Woo Kim¹, Young Hwan Kim¹, Hook Sun¹, Soo Jin Jung²

Departments of ¹Plastic and Reconstructive Surgery and ²Pathology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea

Correspondence: Young Hwan Kim
Department of Plastic and Reconstructive Surgery, Busan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 614-735, Korea
Tel: +82-51-890-6136, Fax: +82-51-894-7976
E-mail: hwanps77@hanmail.net

No potential conflict of interest relevant to this article was reported.

Received: 2 Nov 2012 • Revised: 11 Dec 2012 • Accepted: 31 Dec 2012
pISSN: 2234-6163 • eISSN: 2234-6171
http://dx.doi.org/10.5999/aps.2013.40.2.162
Arch Plast Surg 2013;40:162-164
Copyright © 2013 The Korean Society of Plastic and Reconstructive Surgeons
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hemangiopericytoma is rare in occurrence worldwide, including Korea. It was initially described by Stout and Murrany [1] in 1942. It is derived from a type of smooth muscle cell attached to pericytoma, capillaries also known as Zimmerman pericytes, and it is characterized by a "staghorn" shape on microscopic findings, in other words, a tumor with a diffuse pattern of branching, and dilated, thin-walled blood vessels surrounded by short spindle cells. Hemangiopericytoma has the very unusual characteristic of growing slowly, mainly in the lower extremities and pelvic retroperitoneum, but it can also be found in any part of the body such as the head and neck [1,2]. We...